Whole avian-origin reverse genetic system and recombinant H5N2 subtype avian influenza virus, vaccine and uses thereof

US11512117B1 · kind B1 · utility

Assignee

• SOUTH CHINA AGRICULTURAL UNIVERSITY · CN

Inventors

• Wenbao Qi · Longbeilingcun, CN
• Ming LIAO · Taipei, TW
• Yiqun Chen · Shanghai, CN
• Jiahao Zhang · Puning, CN
• Bo Li · San Jose, US
• Jinyu Huang · Bolingbrook, US
• Huanan Li · Longbeilingcun, CN

Key dates

• Filing date: Apr 22, 2022
• Grant date: Nov 29, 2022
• Expiry date: Apr 22, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/16163
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure discloses a whole avian-origin reverse genetic system, a recombinant H5N2 subtype avian influenza virus, a vaccine containing the virus, and a preparation method and application thereof. The genome of the recombinant virus is comprised of a modified HA gene derived from a highly pathogenic H5N6 subtype avian influenza virus strain, as well as PB2, PB1, PA, NP, NA, M and NS genes derived from H5N2 subtype avian influenza D7 virus strain. The recombinant virus is a recombinant H5N2 avian influenza virus rescued from the D7 virus strain as a backbone, which is an avirulent virus strain with the original immunogenicity, and can maintain a high virus titer during the chick embryo culture process. The recombinant virus fully meets the biological safety requirements and has a good application prospect.